Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Clinical trial NCT07572136 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07572136
- Sponsor
- National Cancer Institute (NCI)
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-23
- Primary completion
- 2030-06-30
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.